DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Otros (Other)
From fragments to drugs: How AI and in silico methods accelerate fragment-to-lead optimization
Fragment-based drug design (FBDD) has become a key approach for mapping chemical space by starting with small, low-affinity fragments and building them into potent leads. Although these fragments bind weakly, strategies like fragment merging and linking can convert them into high-affinity molecules. More recently, Artificial Intelligence (AI) and Machine Learning (ML) have sped up this workflow by powering structure-guided optimization and generative design of new compounds. This review presents the state of FBDD: from biophysical screening and rapid structure elucidation to fragment growing, merging, and linking that elevate affinity while preserving ligand efficiency and drug-like properties. In particular, this review focuses on the integration of AI/ML approaches within these workflows. We compare experimental and computational strategies, summarize representative case studies, and assess how AI/ML now supports hit triage, compound priorization, and efficient exploration of chemical space. By emphasizing the role of AI-driven methods within established FBDD pipelines, we aim to provide a perspective on how these approaches complement traditional strategies. Limitations, common artifacts, and validation practices are discussed to clarify what reliably works and where open challenges remain in FBDD, This research was supported by the EU project Fragment-Screen,
grant agreement ID 101094131, funded by the Horizon Europe pro
gram of the European Commission. CIB–CSIC is an accredited Chemistry
Partner Site of EU-OPENSCREEN ERIC, which is hereby acknowledged., Peer reviewed, Modelo experimental alternativo-NAM, in silico
Proyecto:
EC / HE 101094131